Immunosuppressive therapy in elderly patients with neuromyelitis optica spectrum disorder: a retrospective multicentre study

医学 硫唑嘌呤 中止 不利影响 视神经脊髓炎 美罗华 内科学 回顾性队列研究 入射(几何) 儿科 疾病 免疫学 抗体 淋巴瘤 光学 物理
作者
Ki Hoon Kim,Yeon Hak Chung,Ju‐Hong Min,Hee Jo Han,Seung Woo Kim,Ha Young Shin,Young Nam Kwon,Sung‐Min Kim,Young‐Min Lim,Hyunjin Kim,Eun‐Jae Lee,Seong Ho Jeong,Jae‐Won Hyun,Su‐Hyun Kim,Ho Jin Kim
出处
期刊:Journal of Neurology, Neurosurgery, and Psychiatry [BMJ]
卷期号:95 (12): 1168-1175 被引量:2
标识
DOI:10.1136/jnnp-2024-333644
摘要

Background The risk–benefit relationship of immunosuppressive therapies (ISTs) for elderly patients with neuromyelitis optica spectrum disorder (NMOSD) is not well established. This study aimed to investigate the safety and efficacy of IST in elderly patients with NMOSD. Methods This retrospective study analysed IST efficacy and safety in 101 patients with aquaporin-4 antibody-positive NMOSD aged over 65 years, treated for at least 6 months at five Korean referral centres, focusing on relapse rates, infection events and discontinuation due to adverse outcomes. Results The mean age at disease onset was 59.8 years, and female-to-male ratio was 4:1. Concomitant comorbidities at NMOSD diagnosis were found in 87 patients (86%). The median Expanded Disability Status Scale score at the initiation of IST was 3.5. The administered ISTs included azathioprine (n=61, 60%), mycophenolate mofetil (MMF) (n=48, 48%) and rituximab (n=41, 41%). Over a median of 5.8 years of IST, 58% of patients were relapse-free. The median annualised relapse rate decreased from 0.76 to 0 (p<0.001), and 81% experienced improved or stabilised disability. Patients treated with rituximab had a higher relapse-free rate than those treated with azathioprine or MMF (p=0.022). During IST, 21 patients experienced 25 severe infection events (SIEs) over the age of 65 years, and 3 died from pneumonia. 14 patients (14%) experienced 17 adverse events that led to switching or discontinuation of IST. When comparing the incidence rates of SIEs and adverse events, no differences were observed among patients receiving azathioprine, MMF and rituximab. Conclusion In elderly patients with NMOSD, IST offers potential benefits in reducing relapse rates alongside a tolerable risk of adverse events.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Survivor完成签到,获得积分10
刚刚
3秒前
研友_VZG7GZ应助letter采纳,获得10
3秒前
Hello应助笑哈哈采纳,获得30
3秒前
3秒前
粥粥应助苏苏弋采纳,获得10
4秒前
水流众生发布了新的文献求助10
4秒前
淡然妙松完成签到,获得积分10
4秒前
食虫蚁完成签到 ,获得积分10
6秒前
寂寞的灵波完成签到 ,获得积分10
8秒前
8秒前
ZXH发布了新的文献求助10
9秒前
10秒前
黄哈哈发布了新的文献求助10
11秒前
11秒前
11秒前
13秒前
ZXH完成签到,获得积分10
14秒前
汉堡包应助LexMz采纳,获得10
15秒前
15秒前
15秒前
15秒前
李春鸿发布了新的文献求助10
17秒前
天天发布了新的文献求助100
17秒前
17秒前
小二郎应助genuine采纳,获得10
18秒前
18秒前
19秒前
zhiwei完成签到 ,获得积分0
20秒前
20秒前
20秒前
letter发布了新的文献求助10
20秒前
北城发布了新的文献求助10
20秒前
吃西瓜不吐冬瓜籽完成签到,获得积分10
21秒前
washy发布了新的文献求助10
21秒前
强健的飞瑶完成签到,获得积分10
22秒前
你的风筝应助jjjdcjcj采纳,获得10
22秒前
23秒前
科研通AI2S应助科研通管家采纳,获得10
23秒前
SciGPT应助科研通管家采纳,获得10
23秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988827
求助须知:如何正确求助?哪些是违规求助? 3531197
关于积分的说明 11252739
捐赠科研通 3269830
什么是DOI,文献DOI怎么找? 1804815
邀请新用户注册赠送积分活动 881915
科研通“疑难数据库(出版商)”最低求助积分说明 809028